As of 2017, the IBDX biomarkers: gASCA, ALCA, ACCA, AMCA, Anti-L and Anti-C were analyzed on over 7500 of patient samples in multiple independent clinical studies around the globe, including: Australia, Belgium, Canada, China, Czech Republic, Saudi Arabia, France, Germany, Greece, Hungry, Italy, Israel, Poland and the U.S..
For publications see >>